HTR6 and early-onset autosomal dominant Alzheimer disease: Simultaneous blockade of the dopamine D3 receptor (D3R) is one of the promising strategies in the elaboration of 5-HT6R antagonism-based dual-acting compounds for improved treatment of Alzheimer’s disease and other neurodegenerative disorders [19,20].